Field study for improvement in WHO’s IIEF (The International Index of erectile function) parameters with C23C tablets.

Brief Summary :

The purpose of the multicentric field study was to see the improvement in IIEF parameters with C23C tablets.

Study Design :

We had selected 3 centers namely Jaipur, Lucknow, and Mumbai. The study was done by Physicians / General practitioners on 20 patients.

Method :

Once the doctor concluded through clinical experience and interactions with patients having symptoms of erectile dysfunction, the doctor filled up the IIEF form as prescribed by WHO, this was considered Day 0. If the scores were lower the limit set by WHO the patient had an erectile dysfunction. Other points that were added and in patient information included comorbidities including diabetes, hypertension, anxiety and obesity (calculation based on height and weight).

The patients were advised to be on C23C tablets for a period of 30 days. Post day 30 they were visit the doctor for reassessment of IIEF scores.

Results :

There were no adverse observations reported in any of the patients. Average of IIEF scores and number of attempts per month on day 0 and day 30 mentioned in the chart. There is a remarkable improvement in the scores on day 30 in all 5 functional domains of IIEF and number of attempts per month.

For the use of registered medical practitioner only.

Disclaimer : This is not intended to promote self-medication. Always consult your doctor before taking any medication and / or if signs and symptoms persist.

Field study for improvement in semen quality parameters with C23C tablets

Brief Summary :
The purpose of the multicentric field study was to see the improvement in semen quality in oligospermic patients with C23C tablets.
Study Design :
We had selected 3 centers namely Chapra, Tumkur, and Ahmedabad. The study was done by Gynecologists on 10 patients.
Method :
Once the doctor concluded the male patient to have low sperm count / motility / morphology through a lab report, the patient was advised to be on C23C tablets for period of 90 days. The initial report was considered to be day 0 report. The last report post day 30 was considered to be the final report.
Results :
There were no adverse observations reported in any of the patients. Percentage increase, before and after treatment, in sperm count, sperm motility, and sperm morphology mentioned in the chart. There is significant increase in all 3 semen quality parameters with C23C tablets.

For the use of registered medical practitioner only.


Disclaimer : This is not intended to promote self-medication. Always consult your doctor before taking any medication and / or if signs and symptoms persist.

Enquire Now